Replies to post #106190 on Biotech Values

[jq1234]

In the cabazitaxel study patients who had previously received mitoxantrone were excluded so i imagine the patient population was strictly 1st line and less sick than the patients in the abiraterone study.

Patients in both studies had to be treated with Docetaxel already, so neither could include 1st line patient.

The population difference is marginal.